Analyst Price Targets — GILD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 5, 2026 12:43 pm | — | Truist Financial | $150.00 | $132.76 | TheFly | Gilead price target lowered to $150 from $156 at Truist |
| August 5, 2026 11:41 am | — | RBC Capital | $123.00 | $135.25 | TheFly | Gilead price target raised to $123 from $120 at RBC Capital |
| July 29, 2026 9:07 am | — | Barclays | $145.00 | $134.32 | TheFly | Gilead price target lowered to $145 from $155 at Barclays |
| July 27, 2026 12:07 pm | — | Morgan Stanley | $165.00 | $131.23 | TheFly | Gilead price target lowered to $165 from $166 at Morgan Stanley |
| July 20, 2026 8:18 pm | Daina Graybosch | Leerink Partners | $127.00 | $133.21 | TheFly | Gilead downgraded to Market Perform from Outperform at Leerink |
| July 8, 2026 11:38 am | — | Morgan Stanley | $166.00 | $136.36 | TheFly | Gilead price target lowered to $166 from $168 at Morgan Stanley |
| July 7, 2026 11:20 am | Brian Abrahams | RBC Capital | $120.00 | $129.61 | TheFly | Gilead price target lowered to $120 from $122 at RBC Capital |
| July 6, 2026 5:35 am | Rajesh Kumar | HSBC | $155.00 | $131.27 | StreetInsider | HSBC Upgrades Gilead Sciences (GILD) to Buy |
| June 1, 2026 11:47 am | Brian Abrahams | RBC Capital | $122.00 | $134.43 | StreetInsider | RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD) |
| May 20, 2026 12:15 pm | Michael Okunewitch | Maxim Group | $165.00 | $130.55 | TheFly | Gilead upgraded to Buy at Maxim on approaching growth drivers, valuation |
Latest News for GILD
Gilead (GILD) reported earnings 30 days ago. What's next for the stock?
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Archer Investment Corp acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,578 shares of the biopharmaceutical company's stock, valued at approximately $957,000. A number of other hedge funds
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.